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Abstract
Background: The aim of this study was to evaluate the effects of onion powder consumption on treatment of
Non-alcoholic Fatty Liver Disease (NAFLD) in an experimental model of disease.
Methods: Sprague–Dawley rats were fed high-fat (HF) diet for seven weeks to induce the NAFLD. Then, they were
treated by either the same diet (HF), or high-fat diet plus 7 % onion powder (HF + onion), or chow diet (control), or
chow diet plus 7 % onion powder (control + onion)ad libitum for four weeks. Serum levels of fasting glucose,
triglyceride, cholesterol, liver enzymes, insulin, and hepatic tumor necrosis factor-alpha (TNF-α) gene expression
were determined. Hepatic histology was examined by Hematoxylin and Eosin stain.
Results: Dietary food intakes and weigh gain were significantly more in animals fed control + onion diet in
comparison to the other groups. Animals fed control or control + onion diet had significantly lower plasma levels of
hepatic enzymes, lipid profile, glycemic indices, and hepatic TNF-α gene expression as compared with HF diet fed
groups; however, there was no significant difference in the histopathologic features of NAFLD among different
groups.
Conclusion: Our results indicate that onion consumption can be effective in NAFLD management when it is
combined with a healthy diet.
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Background
Non-alcoholic fatty liver disease (NAFLD), as the most
common liver disease, is becoming anoutstanding public
health concern in the world [1]. NAFLD is strongly asso-
ciated with the features of metabolic syndrome such as
hyperglycemia, central obesity and dyslipidaemia [2]. It
is also associated withincreased risk of all-cause mortal-
ity, contributed by liver relateddeaths as well as non-
liver related causes such as malignancy,diabetes, and car-
diovascular disease [1]. Although the beneficial role of
diet and some dietary supplements on NAFLD treatment
have been shown recently [3–9], no consensus has yet
been achieved. Thus, finding effective therapies are a re-
search priority to reduce the anticipatedburden of liver
diseases [10].
Onion has the potential properties in amelioration of
inflammation, hyperglycemia andhyperlipidemia [11, 12].
Its high content of flavonoids [13], makes it as a great
source of antioxidants and anti-inflammatory agent [14].
It seems that all of these properties can help in treat-
ment of NAFLD. Therefore, the purpose of thepresent
study was to examine the effects of oraladministration of
onion powder on hepatic and serum features of NAFLD
in an experimental model of disease.
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Twenty–four male Sprague–Dawley rats (weighted 120–
150 gram), which were purchased from Pasteur Institute
(Karaj, Iran), were individually housed individually in
wire bar-floor cages. The animals were allowed one week
of acclimatization in a standard environment at 22 °C,
50 % humidity and 12-h light/dark cycles with free ac-
cess to food and water. During the first week, all animals
were fed a standard laboratory chow diet (Pasture Insti-
tute, Iran) and afterwards they fed a high fat, high sugar
diet in seven week for induction of NAFLD [15]. Then,
treatment phase was designed for four weeks. Body
weights (BW) in grams were recorded on arrival and
every two week thereafter. Food intakes were also moni-
tored twice a week. In treatment phase,the animals were
randomly assigned to four groups : first group fed a
standard chow diet (control group) with 10 % of energy
derived from fat, 30 % from protein, and 60 % from car-
bohydrates, second group fed a high-fat, high sugar diet
(HF group) with 59 % of energy derived from fat, 30 %
from carbohydrates, and 11 % from protein, the third
group fed high-fat, high sugar diet added 7 %(w/w)
onion powder (HF + onion group) with 59 % of energy
derived from fat, 31 % from carbohydrates, and 10 %
from protein and finally fourth group fed chow + onion
diet (control + onion) with 10 % of energy derived from
fat, 62 % from carbohydrates, and 28 % from protein.
Groups were fed ad libitum. Onion powder was pre-
pared according to the methods used by Hamauzu et al.
[16]. The diets were prepared weekly and stored as vac-
uum packed (500 g) at −20 °C. Packs taken for use were
thawed in the refrigerator at 4 °C. The food was offered
daily at the beginning of the dark phase, and the remains
were weighed and removed after 48 h.
After eleven-week feeding period, animals were killed
in the overnight fasting state by exsanguination (under
light pentobarbital anesthesia). All animal procedures
were carried out in accordance with the National Nutri-
tion and Food Technology Research Institute (NNFTRI).
The study protocol was approved at NNFTRI ethics
committee with ethics code of NNFTRI 1393–568.
Tissue and blood preparation
Blood samples were collected in heparinized tubes; then,
centrifuged (3500 rpm, 15 min, at 6 °C) to obtain the
plasma. Fasting plasma glucose was measured immedi-
ately, and the remaining samples were kept at −80 °C be-
fore biochemical analysis.
After blood sampling, the livers were excised, washed
with cold physiologic saline (0.9 %), and dried. One lobe
of each liver tissue was preserved in 10 % buffered-
formalin solution for histopathologic examination. Other
liver samples (200 mg) were placed in liquid nitrogen
tank, and then kept at −80 °C for gene expression evalu-
ation [17–20].
RNA extraction and quantitative RT-PCR
Total RNA was purified using RNeasyPlus Mini Kits
(Qiagen) according to the manufacturer’s instructions
and cDNA synthesized with Superscript II reverse tran-
scriptase (Invitrogen). Quantitative real-time PCR was
performed using the Bio-Rad Laboratories MJ mini
Opticon Real-Time PCR System, using IQ SYBR Green
Supermix (Bio-Rad).
Fig. 1 Animal weights in different groups during study. Weight gain was statistically different between four groups (P < 0.05). Weight gain was
significantly more in control + onion group than the other three groups (P < 0.05). HF group weight gain was more than control group (P = 0.002).
Other differences were not statistically significant between groups
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The PCR mix contained 2 μl cDNA, 1 μl of the appro-
priate forward and reverse primers, and 2 μl SYBR Green
PCR Master mix in a total volume of 25 mL. PCR con-
sisted of 50 cycles of denaturation at 94 °C for 30 s, an-
nealing at melting temperature (Tm) for 30 s, and
extension at 72 °C for 60 s. Primer sequences for each tar-
get gene, their source as well as their optimal PCR anneal-
ing temperatures are as follows: GAPDH forward primer
5′-GTGCTGAGTATGTCGTGGAGTCTA-3′ and reverse
5′- TCTCGTGGTTCACACCCATCAC −3′ (Tm 60 °C),
and TNF-α forward primer 5′- ACT GAA CTT CGG
GGT GAT TG −3′ and reverse 5′- GCT TGG TGG TTT
GCT ACG AC −3′ (Tm 60 °C). Primer specificity was
confirmed from the product size by agarose gel
electrophoresis and the specificity of the PCR products
checked by melt curve analysis.
Biochemical assessments
Plasma concentrations of alanine aminotransferase
(ALT), and aspartate aminotransferase (AST) were mea-
sured using optimized UV at 340 nm, and insulin con-
centrations were measured using a rat insulin
radioimmunoassay kit at 4 °C (Linco Research Inc, St
Charles, MO). Plasma glucose and triglyceride were
measured colorimetrically, Gamma glutamyltransferase
(GGT), and Alkaline phosphatase (ALP) assessed photo-
metrically, total Cholestrol, HDL, and LDL cholesterol
Fig. 2 Food intakes in different groups during the study. Food intake was significantly different between four groups in every week (P < 0.01).
Food intake was significantly more in control + onion group than other three groups (P < 0.01). Food intake in control group was less than food
intake in HF group and HF + onion groups (P < 0.01). No difference was seen between HF and HF + onion group in food intake
Table 1 Serum level of hepatic enzymes, lipid and glycemic profiles in different groups at the end of study
HF group
(median (IQR))




Control + onion group
(median (IQR))
P-valued
ALT(IU/L) 57 (47.2–75.7) b,c 62.5 (47.5–76.7) c 50 (29.2–62.7) a,b,c 39 (30.7–49) a 0.05
AST(IU/L) 34 (28–50) b 25 (19.5–35) a,b,c 21.5 (18.5–33) a,c 23.5 (18.7–31.2) c 0.1
GGT (IU/L) 3.9 (3.4–4.6) a 2.9(2.2–3.8) a 3 (2.7–3.2) a 2.8 (2.4–3.4) a 0.1
ALP (IU/L) 890 (754.7–1002)a 937 (812–1098)a 468 (411–542) b 479 (395–635) b 0.002
Glucose (mg/dl) 194 (160–215.7) b 163 (134.7–189.5) a,b,c 150.5(135.2–168.5) a,c 133 (118.5–151) c 0.04
Insulin (pmol/l) 465 (402–512)a 444 (392–506)a 192 (176–219)b 179 (165–202)b 0.01
TG (mg/dl) 135 (118–145) a 124.5 (114.2–149) a,b 102 (88.5–121.5) b,c 83 (70.2–93.2) c 0.001
Cholesterol (mg/dl) 125 (110.7–138)a 122.5 (116–139.7)a 109.5 (98–116) b 104 (96–118.5) b 0.03
HDL-C (mg/dl) 45.5 (31.5–53.5) a 37.5 (29.2–43) a 41.5 (36.5–52.2) a 50.5 (43.7–56) a 0.1
LDL-C (mg/dl) 56.7 (36.7–75.6) a,b 62.5 (51.2–80.4) b 44.9 (33.3–52.5) a,b 39.8 (33.6–50.3) a 0.08
IQR interquartile range, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma glutamine transferase, ALP alkaline phosphatase, TG
triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol
a,b,cIn every row different scripts show significant difference
dKruskal–Wallis test
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were examined enzymatically all by using a commercial
kit (Parsazmoon, Tehran, Iran).
Histopathology
Five sections from different lobes of each liver were sub-
mitted and processed through ethyl alcohol and xylene
series, and embedded in paraffine blocks. Slides were
stained with Hematoxylin and Eosin and Masson's
Trichome and viewed under light microscopy by Nikon
E 200. The grading was defined as follow: for hepatic
steatosis: grade 0, no fat; grade 1, steatosis occupying
less than 33 % of the hepatic parenchyma; grade 2, 34–
66 % of the hepatic parenchyma; grade 3, more than
66 % of the hepatic parenchyma; for inflammatory cell
infiltration: grade 0: none; grade 1, 1–2 foci/field; grade
2, 3–4 foci/field; grade 3, more than 4 foci/field [20]; for
ballooning: minimal, mild, and marked [21].
Statistical analysis
Results are expressed as median (interquartile range)
and using nonparametric tests included Mann Whitney,
Kruskal Wallis and chi-square tests. P < 0.05 was consid-
ered for significance level. All statistical analyses were
performed with the use of either GraphPad Prism Soft-
ware Version 5.00 (GraphPad Software, SanDiego, CA),
or SPSS 20.0 software (Chicago, IL, USA). The raw data
are shown in Additional file 1.
Fig. 3 Hepatic TNF-α m RNA expression comparison among four groups. Different scripts show significant difference
Table 2 Histopathological characteristics of HF, control, HF +
onion and control + onion groups (n = 6 in each group)
Group Stage P value
Low High
Steatosis Control 6 (100) 0 0.06
n (%) HF 3 (50) 3 (50)
HF + onion 5 (83.3) 1 (16.7)
Control + onion 6 (100) 0
Ballooning Control 3 (50) 3 (50) 0.3
n (%) HF 1 (16.7) 5 (83.3)
HF + onion 4 (66.7) 2 (33.3)
Control + onion 3 (50) 3 (50)
Lobular inflammation Control 5 (83.3) 1 (16.7) 0. 5
n (%) HF 3 (50) 3 (50)
HF + onion 4 (66.7) 2 (33.3)
Control + onion 5 (83.3) 1 (16.7)
Portal inflammation Control 4 (66.7) 2 (33.3) 0. 5
n (%) HF 3 (50) 3 (50)
HF + onion 3 (50) 3 (50)
Control + onion 5 (83.3) 1 (16.7)
Low = 0 or 1 stage
High = 2 or 3 stage
HF high fat
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Results
Weight gain was measured and compared between four
groups in beginning, second and fourth weeks of treat-
ment phase (Fig. 1). Weight gain was statistically different
between four groups (P < 0.05). Weight gain was signifi-
cantly more in control + onion group than the other three
groups (P < 0.05). Also, HF group weight gain was more
than control group (P = 0.002). Other differences were not
statistically significant between groups.
Figure 2 shows the food intakes of different groups dur-
ing the study. Kruskal–Wallis test showed that food intake
was significantly different among four groups in every week
(P < 0.01). Food intake was significantly more in control +
onion group than other three groups (P < 0.01). Food intake
in control group was less than food intake in model group
and HF + onion groups (P < 0.01).No difference was seen
between HF and HF + onion group in food intake.
Table 1 shows the plasma levels of hepatic enzymes,
glycemic, and lipid profile in the four groups at the end
of the study. HF group had significantly higher plasma
level of AST (P = 0.05),TG (P = 0.01), glucose (P = 0.02),
cholesterol (P = 0.04) and ALP (P = 0.004) compared
with control group. Adding onion to control group de-
creased ALT in comparison with HF group(P = 0.02).
Control and control + onion groups were similar except
in TG that was less in control + onion compared to con-
trol group (P = 0.02). Adding onion to HF diet could not
cause any significant changes as compared with HF diet.
Hepatic TNF-α gene expression was not signifi-
cantly decreased in HF + onion group in comparison
to HF group. Treatment by chow or chow + onion
could significantly reduce hepatic TNF-α gene expres-
sion (P < 0.05) (Fig. 3).
As shown in Table 2 and Fig. 4, no significant differ-
ence was seen among four groups in hepatologic indices
(steatosis, ballooning, lobular inflammation and portal
inflammation) after four weeks of treatment.
Discussion
Our results have shown that onion consumption can at-
tenuate the risk factors of NAFLD; however, these effects
were not statistically significant without accompanying
with a healthy diet. Onion can ameliorate the lipid profile,
glycemic, and inflammatory indices through its antioxi-
dant, anti-inflammatory, hypoglycemic and hypolipidemic
effects [16, 22–26], but these improvements were not sta-
tistically different from control group because the animals
who consumed onion, their food intake and weight gain
were more than those without onion supplementation.
Since body weight plays a pivotal role in the pathogenesis
A B
C D
Fig. 4 Hepatic pathology in rats fed control + 7 % onion × 100 (a) fed high fat, high sugar diets ad libitum × 100 (b) fed chow diet ad libitum ×
100 (c) and fed high fat, high sugar diets + 7 % onion × 100 (d). The liver samples were stained with Hematoxylin and Eosin
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of NAFLD [5], it is possible that those animals who re-
ceived onion, liked its taste and ate more foods, resulting
to more weight gain so that the beneficial effects of onion
were weakened due to the adverse effects of high food
consumption and weight gain.
The animals in control groups whom fed the chow
diet with or without onion had significantly lower
plasma levels of hepatic enzymes, glycemic and lipid in-
dices, and hepatic TNF-α gene expression, which con-
firms the pivotal role of diet and weight in the NAFLD
management [5]. The effects of onion on the growth
performance and appetite enhancement have been
shown previously [27, 28]; however, some of its compo-
nents act inversely and reduce the body weight [29]. Our
results confirm that the whole onion can be used as a
growth promoter; however, some of its components may
have anti obesity properties.
Conclusion
In conclusion, our results indicate that adding onion to
the diet increases the dietary intakes and weight gain,
which contradicts its antioxidant, anti-inflammatory,
hypoglycemic and hypolipidemic effects in NAFLD man-
agement. Thus, onion consumption can help in NAFLD
management when it is combined with a healthy diet.
Further studies are needed to explorethe effects of differ-
ent types of onion on NAFLD management.
Additional file
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